{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:34Z","timestamp":1792785994981,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Rosalie and Harold Rea Brown Endowed Chair (to RE) and the National Cancer Institute at the National Institutes of Health","award":["R50 CA221836"],"award-info":[{"award-number":["R50 CA221836"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multicancer early detection (MCED) tests may soon be available to screen for many cancers using a single blood test, yet little is known about these tests beyond their diagnostic performance. Taking lessons from the history of cancer early detection, we highlight 3 factors that influence how performance of early detection tests translates into benefit and benefit-harm trade-offs: the ability to readily confirm a cancer signal, the population testing strategy, and the natural histories of the targeted cancers. We explain why critical gaps in our current knowledge about each factor prevent reliably projecting the expected clinical impact of MCED testing at this point in time. Our goal is to communicate how much uncertainty there is about the possible effects of MCED tests on population health so that patients, providers, regulatory agencies, and the public are well informed about what is reasonable to expect from this potentially important technological advance. We also urge the community to invest in a coordinated effort to collect data on MCED test dissemination and outcomes so that these can be tracked and studied while the tests are rigorously evaluated for benefit, harm, and cost.<\/jats:p>","DOI":"10.1093\/jnci\/djab168","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T18:45:15Z","timestamp":1630089915000},"page":"349-352","source":"Crossref","is-referenced-by-count":63,"title":["Multicancer Early Detection: Learning From the Past to Meet the Future"],"prefix":"10.1093","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-6370","authenticated-orcid":false,"given":"Ruth","family":"Etzioni","sequence":"first","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"},{"name":"Center for Early Detection Advanced Research, Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-6567","authenticated-orcid":false,"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel S","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"},{"name":"Department of Epidemiology, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"issue":"6378","key":"2022030807401437900_djab168-B1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"7761","key":"2022030807401437900_djab168-B2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"issue":"6","key":"2022030807401437900_djab168-B3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"2022030807401437900_djab168-B4","first-page":"141","volume-title":"Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications","author":"Pepe","year":"2002"},{"issue":"3","key":"2022030807401437900_djab168-B5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.seminoncol.2010.05.006","article-title":"Principles of cancer screening: lessons from history and study design issues","volume":"37","author":"Croswell","year":"2010","journal-title":"Semin Oncol"},{"issue":"5","key":"2022030807401437900_djab168-B6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2022030807401437900_djab168-B7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Ann Intern Med"},{"issue":"10","key":"2022030807401437900_djab168-B8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force Recommendation Statement","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"2022030807401437900_djab168-B9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1001\/jama.2021.1077","article-title":"Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force","volume":"325","author":"Meza","year":"2021","journal-title":"JAMA"},{"issue":"23","key":"2022030807401437900_djab168-B10","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1001\/jama.2016.5989","article-title":"Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement","volume":"315","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"2022030807401437900_djab168-B11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: U.S. Preventive Services Task Force Recommendation statement","volume":"164","author":"Siu","year":"2016","journal-title":"Ann Intern Med"},{"issue":"15","key":"2022030807401437900_djab168-B12","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2001.19.15.3490","article-title":"Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations","volume":"19","author":"Shen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022030807401437900_djab168-B13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.28623","article-title":"Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials","volume":"120","author":"Meza","year":"2014","journal-title":"Cancer"},{"issue":"12","key":"2022030807401437900_djab168-B14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer","volume":"95","author":"Draisma","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2022030807401437900_djab168-B15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1055-9965.EPI-19-1366","article-title":"Projected reductions in absolute cancer-related deaths from diagnosing cancers before metastasis, 2006-2015","volume":"29","author":"Clarke","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"35","key":"2022030807401437900_djab168-B16","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1200\/JCO.2009.22.7041","article-title":"Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening","volume":"27","author":"Autier","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022030807401437900_djab168-B17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.eururo.2012.05.068","article-title":"Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"62","author":"Schroder","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"2022030807401437900_djab168-B18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/EDE.0000000000000272","article-title":"Commentary: cohort studies of the efficacy of screening for cancer","volume":"26","author":"Weiss","year":"2015","journal-title":"Epidemiology"},{"issue":"4","key":"2022030807401437900_djab168-B19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.ede.0000129518.99816.e1","article-title":"Case-control studies of the efficacy of cancer screening: overcoming bias from nonrandom patterns of screening","volume":"15","author":"Weiss","year":"2004","journal-title":"Epidemiology"},{"issue":"4","key":"2022030807401437900_djab168-B20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MLR.0b013e31827da979","article-title":"Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening","volume":"51","author":"Etzioni","year":"2013","journal-title":"Med Care"},{"issue":"9","key":"2022030807401437900_djab168-B21","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.22607","article-title":"Reconstructing prostate-specific antigen (PSA) testing patterns among Black and White men in the US from Medicare claims and the National Health Interview Survey","volume":"109","author":"Mariotto","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2022030807401437900_djab168-B22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0272989X07312719","article-title":"Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach","volume":"28","author":"Etzioni","year":"2008","journal-title":"Med Decis Making"},{"issue":"1","key":"2022030807401437900_djab168-B23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1541-0420.2007.00825.x","article-title":"Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends","volume":"64","author":"Telesca","year":"2008","journal-title":"Biometrics"},{"issue":"13","key":"2022030807401437900_djab168-B24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMe0901166","article-title":"Screening for prostate cancer\u2013the controversy that refuses to die","volume":"360","author":"Barry","year":"2009","journal-title":"N Engl J Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djab168\/40405282\/djab168.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/3\/349\/42756465\/djab168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/3\/349\/42756465\/djab168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T02:41:27Z","timestamp":1646707287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/114\/3\/349\/6358734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,8,27]]},"published-print":{"date-parts":[[2022,3,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djab168","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,27]]}}}